I think a nice upfront payment and then ongoing revenue somewhere between 15-20% ... as many have re-iterated on here, Starpharma have taken Vivagel for BV through to phase III and now commercialisation on their own, so IMO judging from their negotiating capabilities with the Agrochem sale, we won't be disappointed in the outcome
Vivagel BV treatment and prevention, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.17M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28056 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 1285 | 1 |
View Market Depth
| Last trade - 07.00am 27/08/2024 (20 minute delay) ? |
| SPL (ASX) Chart |
Day chart unavailable